Hemogenyx Pharmaceuticals Plc (HEMO:LSE) Investor Relations Material

Overview

Hemogenyx Pharmaceuticals is a UK-based preclinical-stage biotech company focused on developing therapies and treatments for blood diseases, particularly for the bone marrow/hematopoietic stem cell transplant market. The company's products target acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, amongst others. Hemogenyx is also developing chimeric antigen receptor T-cells for use in immunotherapy, and stem cell therapy products for bone marrow transplants. Hemogenyx has a collaboration with GlobalCo and was incorporated in 2013.

Annual Reports

Frequently Asked Questions

What is Hemogenyx Pharmaceuticals Plc's ticker?

Hemogenyx Pharmaceuticals Plc's ticker is HEMO

What exchange is Hemogenyx Pharmaceuticals Plc traded on?

The company's shares trade on the LSE stock exchange

Where are Hemogenyx Pharmaceuticals Plc's headquarters?

They are based in London, England

How many employees does Hemogenyx Pharmaceuticals Plc have?

There are 1-10 employees working at Hemogenyx Pharmaceuticals Plc

What is Hemogenyx Pharmaceuticals Plc's website?

It is https://hemogenyx.com/

What type of sector is Hemogenyx Pharmaceuticals Plc?

Hemogenyx Pharmaceuticals Plc is in the Healthcare sector

What type of industry is Hemogenyx Pharmaceuticals Plc?

Hemogenyx Pharmaceuticals Plc is in the Biotechnology industry

Who are Hemogenyx Pharmaceuticals Plc's peers and competitors?

The following five companies are Hemogenyx Pharmaceuticals Plc's industry peers:

- Exopharm Limited

- Intec Pharma

- Arcus Biosciences

- Coherus BioSciences

- Cabaletta Bio, Inc.